CBLB sirna

CBLB siRNA (Rat)

Cat. Num. AAA8233704

• Reactivity: Rat
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: CBLB; CBLB siRNA (Rat); E3 ubiquitin-protein ligase CBL-B; Casitas B-lineage lymphoma proto-oncogene b; SH3-binding protein CBL-B; Signal transduction protein CBL-B; CBLB sirna

• Host: Synthetic
• Reactivity: Rat
• Specificity: CBLB siRNA (Rat) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 938

• Applicable Applications for CBLB sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of rat CBLB gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for CBLB sirna

siRNA to inhibit CBLB expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 29789319
• NCBI GeneID: 171136
• NCBI Accession #: NP_598285.1
• NCBI GenBank Nucleotide #: NM_133601.1
• UniProt Accession #: Q8K4S7; Q9QZ69
• Molecular Weight: 104,652 Da
• NCBI Official Full Name: E3 ubiquitin-protein ligase CBL-B
• NCBI Official Synonym Full Names: Cbl proto-oncogene B, E3 ubiquitin protein ligase
• NCBI Official Symbol: Cblb
• NCBI Protein Information: E3 ubiquitin-protein ligase CBL-B
• UniProt Protein Name: E3 ubiquitin-protein ligase CBL-B
• Protein Family: E3 ubiquitin-protein ligase
• UniProt Gene Name: Cblb
• UniProt Entry Name: CBLB_RAT

NCBI Description

ubiquitin-protein ligase; may regulate autoimmunity; implicated as a susceptibility gene for type I diabetes (IDDM) [RGD, Feb 2006]

Uniprot Description

Cbl-b: E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. Negatively regulates TCR (T-cell receptor), BCR (B- cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. In naive T-cells, inhibits VAV1 activation upon TCR engagement and imposes a requirement for CD28 costimulation for proliferation and IL-2 production. Also acts by promoting PIK3R1/p85 ubiquitination, which impairs its recruitment to the TCR and subsequent activation. In activated T- cells, inhibits PLCG1 activation and calcium mobilization upon restimulation and promotes anergy. In B-cells, acts by ubiquitinating SYK and promoting its proteasomal degradation. May also be involved in EGFR ubiquitination and internalization. Interacts with SH3 domain-containing proteins LCK, CRK and SORBS1. Interacts with LCP2 and ZAP70. May interact with CBL. Interacts with SH3 domain-containing proteins VAV1, FYN, FGR, PLCG1, GRB2, CRKL, PIK3R1 and SH3KBP1/CIN85. Identified in heterotrimeric complexes with SH3KBP1/CIN85, CD2AP and ARHGEF7, where one CBLB peptide binds two copies of the other protein. Interacts with poly-ubiquitinated proteins. Dimerization is required for the binding of poly-ubiquitin, but not for the binding of mono-ubiquitin. Expressed in placenta, heart, lung, kidney, spleen, ovary and testis, as well as fetal brain and liver and hematopoietic cell lines, but not in adult brain, liver, pancreas, salivary gland, or skeletal muscle. Present in lymphocytes. 4 isoforms of the human protein are produced by alternative splicing.

Protein type: Ubiquitin conjugating system; Adaptor/scaffold; Ligase; Ubiquitin ligase; EC 6.3.2.-; Calcium-binding

Cellular Component: nucleoplasm; cytoplasm; intracellular; nucleus; lipid raft

Molecular Function: signal transducer activity; phosphotyrosine binding; zinc ion binding; ubiquitin-protein ligase activity; calcium ion binding; protein kinase binding; ligase activity

Biological Process: response to gravity; cell surface receptor linked signal transduction; T cell activation; positive regulation of protein catabolic process; response to hormone stimulus; protein ubiquitination; negative regulation of T cell receptor signaling pathway; negative regulation of alpha-beta T cell proliferation; immune response; signal transduction; positive regulation of T cell anergy